Aqua Pharma acquires Verdeso Foam from GSK

West Chester-based, USA, Aqua Pharmaceuticals says it has acquired the US rights to, and re-launch of, Verdeso (desonide) Foam, 0.05% from Stiefel, a subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK). Financial terms of the deal were not disclosed.

Verdeso Foam is the only low-potency corticosteroid foam indicated for the topical treatment of mild to moderate atopic dermatitis in patients three months of age and older. The emollient-based and ethanol-free Verdeso Foam is unavailable in generic form. Aqua will assume control of all manufacturing and distribution, as well as promotion of the product through its own national dermatology-specialty sales force.

“Verdeso is the perfect complement to our already robust dermatology line,” said Craig Ballaron, chief executive of Aqua, a portfolio company of RoundTable Healthcare Partners, adding: “Our portfolio has products formulated in a variety of vehicles: Monodox Capsules, Xolegel Gel, Fluoroplex Topical Cream and Cordran Cream and Lotion. We were missing a foam formulation in our product offering, and we believe Verdeso Foam will give physicians more physicians more prescribing options.”